vs
Side-by-side financial comparison of Emerson Electric (EMR) and Zoetis (ZTS). Click either name above to swap in a different company.
Emerson Electric is the larger business by last-quarter revenue ($4.3B vs $2.4B, roughly 1.8× Zoetis). Zoetis runs the higher net margin — 25.3% vs 13.9%, a 11.3% gap on every dollar of revenue. On growth, Emerson Electric posted the faster year-over-year revenue change (4.1% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $602.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -0.3%).
Emerson ElectricEMREarnings & Financial Report
Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EMR vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.3B | $2.4B |
| Net Profit | $605.0M | $603.0M |
| Gross Margin | 53.2% | 70.2% |
| Operating Margin | 17.8% | 31.9% |
| Net Margin | 13.9% | 25.3% |
| Revenue YoY | 4.1% | 3.0% |
| Net Profit YoY | 3.4% | 3.8% |
| EPS (diluted) | $1.07 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.3B | $2.4B | ||
| Q3 25 | $4.9B | $2.4B | ||
| Q2 25 | $4.6B | $2.5B | ||
| Q1 25 | $4.4B | $2.2B | ||
| Q4 24 | $4.2B | $2.3B | ||
| Q3 24 | $4.6B | $2.4B | ||
| Q2 24 | $4.4B | $2.4B | ||
| Q1 24 | $4.4B | $2.2B |
| Q4 25 | $605.0M | $603.0M | ||
| Q3 25 | $637.0M | $721.0M | ||
| Q2 25 | $586.0M | $718.0M | ||
| Q1 25 | $485.0M | $631.0M | ||
| Q4 24 | $585.0M | $581.0M | ||
| Q3 24 | $996.0M | $682.0M | ||
| Q2 24 | $329.0M | $624.0M | ||
| Q1 24 | $501.0M | $599.0M |
| Q4 25 | 53.2% | 70.2% | ||
| Q3 25 | 51.9% | 71.5% | ||
| Q2 25 | 52.6% | 73.6% | ||
| Q1 25 | 53.5% | 72.0% | ||
| Q4 24 | 53.5% | 69.5% | ||
| Q3 24 | 51.3% | 70.6% | ||
| Q2 24 | 52.8% | 71.7% | ||
| Q1 24 | 52.2% | 70.6% |
| Q4 25 | 17.8% | 31.9% | ||
| Q3 25 | 16.4% | 37.0% | ||
| Q2 25 | 16.1% | 36.7% | ||
| Q1 25 | 14.2% | 36.5% | ||
| Q4 24 | 18.6% | 31.6% | ||
| Q3 24 | 14.7% | 36.6% | ||
| Q2 24 | 10.4% | 33.0% | ||
| Q1 24 | 16.2% | 34.1% |
| Q4 25 | 13.9% | 25.3% | ||
| Q3 25 | 13.1% | 30.0% | ||
| Q2 25 | 12.9% | 29.2% | ||
| Q1 25 | 10.9% | 28.4% | ||
| Q4 24 | 14.0% | 25.1% | ||
| Q3 24 | 21.6% | 28.6% | ||
| Q2 24 | 7.5% | 26.4% | ||
| Q1 24 | 11.4% | 27.4% |
| Q4 25 | $1.07 | $1.37 | ||
| Q3 25 | $1.12 | $1.63 | ||
| Q2 25 | $1.04 | $1.61 | ||
| Q1 25 | $0.86 | $1.41 | ||
| Q4 24 | $1.02 | $1.29 | ||
| Q3 24 | $1.74 | $1.50 | ||
| Q2 24 | $0.57 | $1.37 | ||
| Q1 24 | $0.87 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $7.6B | — |
| Stockholders' EquityBook value | $20.3B | $3.3B |
| Total Assets | $41.9B | $15.5B |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $7.6B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $8.2B | — | ||
| Q4 24 | $6.6B | — | ||
| Q3 24 | $7.7B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $7.6B | — |
| Q4 25 | $20.3B | $3.3B | ||
| Q3 25 | $20.3B | $5.4B | ||
| Q2 25 | $19.9B | $5.0B | ||
| Q1 25 | $19.2B | $4.7B | ||
| Q4 24 | $20.5B | $4.8B | ||
| Q3 24 | $21.6B | $5.2B | ||
| Q2 24 | $20.8B | $5.0B | ||
| Q1 24 | $20.9B | $5.1B |
| Q4 25 | $41.9B | $15.5B | ||
| Q3 25 | $42.0B | $15.2B | ||
| Q2 25 | $42.5B | $14.5B | ||
| Q1 25 | $42.0B | $14.1B | ||
| Q4 24 | $42.6B | $14.2B | ||
| Q3 24 | $44.2B | $14.4B | ||
| Q2 24 | $45.6B | $14.2B | ||
| Q1 24 | $46.4B | $14.3B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $699.0M | $893.0M |
| Free Cash FlowOCF − Capex | $602.0M | $732.0M |
| FCF MarginFCF / Revenue | 13.9% | 30.7% |
| Capex IntensityCapex / Revenue | 2.2% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.16× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $4.4B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $699.0M | $893.0M | ||
| Q3 25 | $3.1B | $938.0M | ||
| Q2 25 | $1.1B | $486.0M | ||
| Q1 25 | $241.0M | $587.0M | ||
| Q4 24 | $777.0M | $905.0M | ||
| Q3 24 | $3.3B | $951.0M | ||
| Q2 24 | $1.1B | $502.0M | ||
| Q1 24 | $743.0M | $595.0M |
| Q4 25 | $602.0M | $732.0M | ||
| Q3 25 | $2.7B | $805.0M | ||
| Q2 25 | $977.0M | $308.0M | ||
| Q1 25 | $154.0M | $438.0M | ||
| Q4 24 | $694.0M | $689.0M | ||
| Q3 24 | $2.9B | $784.0M | ||
| Q2 24 | $998.0M | $370.0M | ||
| Q1 24 | $661.0M | $455.0M |
| Q4 25 | 13.9% | 30.7% | ||
| Q3 25 | 54.9% | 33.5% | ||
| Q2 25 | 21.5% | 12.5% | ||
| Q1 25 | 3.5% | 19.7% | ||
| Q4 24 | 16.6% | 29.7% | ||
| Q3 24 | 63.1% | 32.8% | ||
| Q2 24 | 22.8% | 15.7% | ||
| Q1 24 | 15.1% | 20.8% |
| Q4 25 | 2.2% | 6.7% | ||
| Q3 25 | 8.9% | 5.5% | ||
| Q2 25 | 2.0% | 7.2% | ||
| Q1 25 | 2.0% | 6.7% | ||
| Q4 24 | 2.0% | 9.3% | ||
| Q3 24 | 9.1% | 7.0% | ||
| Q2 24 | 2.1% | 5.6% | ||
| Q1 24 | 1.9% | 6.4% |
| Q4 25 | 1.16× | 1.48× | ||
| Q3 25 | 4.86× | 1.30× | ||
| Q2 25 | 1.83× | 0.68× | ||
| Q1 25 | 0.50× | 0.93× | ||
| Q4 24 | 1.33× | 1.56× | ||
| Q3 24 | 3.35× | 1.39× | ||
| Q2 24 | 3.31× | 0.80× | ||
| Q1 24 | 1.48× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EMR
| Other | $1.8B | 41% |
| Software And Systems | $1.0B | 24% |
| Intelligent Devices | $996.0M | 23% |
| Safety And Productivity | $503.0M | 12% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
